论文部分内容阅读
目的 :测定 2型糖尿病和冠心病患者血浆促酰化蛋白 (ASP)水平 ,探讨血浆ASP与体重指数、血脂的相关关系。方法 :实验分 3组 :正常对照组 47例、糖尿病组 63例、冠心病组 62例 ,记录每例被试对象的年龄、性别、身高、体重、血压 ,并计算体重指数 (BMI)。酶联免疫吸附分析法 (ELISA)检测血浆ASP浓度 ,免疫比浊法检测血脂等生化指标。结果 :①糖尿病组、冠心病组ASP水平明显高于正常对照组 (P <0 0 5 )。②ASP与体重指数、收缩压、舒张压、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、载脂蛋白B10 0呈显著正相关 (分别为r =0 3 2 ,P <0 0 1;r =0 2 4,P <0 0 1;r =0 19,P <0 0 1;r =0 3 5 ,P <0 0 1;r =0 10 ,P <0 0 5 ;r =0 2 9,P <0 0 1;r =0 3 2 ,P <0 0 1)。③多元逐步回归分析 :载脂蛋白B10 0、体重指数、高密度脂蛋白胆固醇和舒张压最终进入方程 ,它们是影响血浆ASP水平的重要因素 ,其中载脂蛋白B10 0的作用最大。结论 :ASP参与了糖尿病和冠心病患者脂质代谢紊乱的发生 ,血浆ASP水平可能作为估价糖尿病患者发生心血管疾病危险性的新指标
Objective: To determine the levels of serum acyl-stimulating protein (ASP) in type 2 diabetes mellitus and patients with coronary heart disease and to explore the relationship between plasma ASP and body mass index and blood lipids. Methods: The experiment was divided into three groups: 47 cases of normal control group, 63 cases of diabetes mellitus group and 62 cases of coronary heart disease group. The age, sex, height, weight, blood pressure and body mass index (BMI) of each sample were recorded. Serum ASP concentration was measured by enzyme-linked immunosorbent assay (ELISA), and biochemical parameters such as serum lipids were detected by immunoturbidimetry. Results: ① The levels of ASP in diabetic group and coronary heart disease group were significantly higher than those in normal control group (P <0.05). ② There was a significant positive correlation between AS and body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, triglyceride, low density lipoprotein cholesterol, and apolipoprotein B10 0 (r = 0 3 2, P <0 0 1; r = 0 10, P <0 0 5; r = 0 2 9, P 0 01; P <0 0 1; r = 0 3 2, P <0 0 1). Multiple stepwise regression analysis: apolipoprotein B10 0, body mass index, high density lipoprotein cholesterol and diastolic pressure eventually entered the equation, which are important factors affecting plasma ASP levels, of which apolipoprotein B10 0 has the greatest effect. Conclusion: ASP participates in the occurrence of lipid metabolism disorder in patients with diabetes mellitus and coronary heart disease. Plasma ASP level may be used as a new index to evaluate the risk of cardiovascular disease in diabetic patients